Effects on energy utilization of a ß3-adrenergic agonist in rats fed on a cafeteria diet
- 1 September 1997
- journal article
- research article
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 2 (3) , 130-137
- https://doi.org/10.1007/bf03339963
Abstract
The antiobesity potential of a new ß3-adrenergic agonist (Trecadrine) was assessed in a cafeteria model of obesity through body composition, thermogenesis and oxygen consumption indicators. Animals fed on a cafeteria diet for 75 days increased body weight and fat content, while muscle mass as a percentage of body weight was reduced in relation to control fed rats. In addition, in vitro brown adipose tissue (BAT) and white adi pose tissue (WAT) oxygen consumption was increased in these obese animals as compared with controls. Trecadrine administration reduced weight gain, BAT and WAT stores as wel as the respiratory quotient, which was accompanied by an increase in WAT and BAT oxygen consumption and rectal temperature. Moreover, muscle mass as a percentage of body weigh maintained the same values as non-obese animals, while an increase in absolute muscle weight was found in Trecadrine-treated obese rats. However, liver weights and in vitro oxygen consumption remained unaltered after cafeteria feeding and Trecadrine administration Since chronic administration of Trecadrine had no effect on food intake, the stimulation o thermogenesis and oxygen consumption by the ß3-adrenergic agonist in white and brown adipose tissue are apparently responsible for the rise in energy expenditure as well as for the lower weight gain and fat deposition in obese treated rats. Thus, Trecadrine exhibits some promise as a potential treatment for obesity.Keywords
This publication has 31 references indexed in Scilit:
- Potential anti-diabetic applications of a new molecule with affinity for β3-AdrenoceptorsLife Sciences, 1996
- Current views on obesityThe American Journal of Medicine, 1996
- Desensitization effect of in vivo treatment with metaproterenol on β1, β2 and β3-adrenergic responsiveness in rat adipocytesLife Sciences, 1995
- Pharmacologic Treatment of Obesity: Symposium OverviewObesity Research, 1995
- β‐Agonists as Antiobesity, Antidiabetic and Nutrient Partitioning AgentsObesity Research, 1995
- Antiobesity and Antidiabetic β‐agonists: Lessons Learned and Questions to be AnsweredObesity Research, 1994
- Anti-obesity and anti-diabetic effects of CL 316, 243, a highly specific β3-adrenoceptor agonist, in yellow KK miceLife Sciences, 1994
- Determination of Body Composition in Growing Rats by Total Body Electrical ConductivityJournal of Pediatric Gastroenterology and Nutrition, 1992
- Changes in Serum and Urinary Amino Acids after the Administration of a Mixed Beta-Adrenergic AgonistAnnals of Nutrition and Metabolism, 1992
- Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830ACanadian Journal of Physiology and Pharmacology, 1987